SEC Comment Letter 0000000000-24-000330 to BridgeBio Oncology Therapeutics, Inc. (BBOT)
BridgeBio Oncology Therapeutics, Inc.
Date: Jan. 10, 2024 · CIK: 0001869105 · Accession: 0000000000-24-000330
AI Filing Summary & Sentiment
Show Raw Text
United States securities and exchange commission logo
January 10, 2024
Bihua Chen
Chief Executive Officer
Helix Acquisition Corp. II
200 Clarendon Street, 52nd Floor
Boston, MA 02116
Re:Helix Acquisition Corp. II
Draft Registration Statement on Form S-1
Submitted December 20, 2023
CIK No. 0001869105
Dear Bihua Chen:
We have reviewed your draft registration statement and have the following comments.
Please respond to this letter by providing the requested information and either submitting
an amended draft registration statement or publicly filing your registration statement on
EDGAR. If you do not believe a comment applies to your facts and circumstances or do not
believe an amendment is appropriate, please tell us why in your response.
After reviewing the information you provide in response to this letter and your amended
draft registration statement or filed registration statement, we may have additional comments.
Draft Registration Statement on Form S-1 submitted December 20, 2023
We may issue our shares to investors in connection with our initial business combination...., page
47
1.We note your disclosure here and your references to PIPE transactions elsewhere. Please
clearly disclose their impact to you and investors. To the extent you may utilize PIPE
transactions, disclose that the agreements are intended to ensure a return on investment to
the investor in return for funds facilitating the sponsor’s completion of the business
combination or providing sufficient liquidity. Additionally, please also disclose that these
arrangements result in costs particular to the de-SPAC process that would not be
anticipated in a traditional IPO. Lastly, please clarify here and throughout the prospectus
whether the PIPE transactions may occur at a price below the IPO price of $10 per share
and if so, the resultant risks.
FirstName LastNameBihua Chen
Comapany NameHelix Acquisition Corp. II
January 10, 2024 Page 2
FirstName LastName
Bihua Chen
Helix Acquisition Corp. II
January 10, 2024
Page 2
The new 1% U.S. federal excise tax on stock buybacks could be imposed...., page 69
2.We note that this risk factor describes the potential material effect on your shareholders of
the stock buyback excise tax enacted as part of the Inflation Reduction Act of August
2022. Please also describe the risks of the excise tax applying to redemptions in
connection with:
•liquidations that are not implemented to fall within the meaning of “complete
liquidation” in Section 331 of the Internal Revenue Code;
•extensions, depending on the timing of the extension relative to when the SPAC
completes a de-SPAC or liquidates; and
•de-SPACs, depending on the structure of the de-SPAC transaction.
Our amended and restated memorandum and articles of association provide that the courts of the
Cayman Islands will be the exclusive...., page 72
3.Please reconcile the disclosure in this risk factor that "the forum selection provision in our
amended and restated memorandum and articles of association will not apply to actions or
suits brought to enforce any liability or duty created by the Securities Act, Exchange Act
or any claim for which the federal district courts of the United States are, as a matter of
the laws of the United States, the sole and exclusive forum for determination of such a
claim" with the disclosure on page 139 that "our amended and restated memorandum and
articles of association also provide that, unless we consent in writing to the selection of an
alternative forum, to the fullest extent permitted by law, the federal district courts of the
United States will be the exclusive forum for the resolution of any complaint asserting a
cause of action arising under the federal securities laws of the United States, including
those arising under the Securities Act or Exchange Act."
Permitted Purchases of Our Securities, page 97
4.We note that unlike traditional SPACs, your offering does not include warrants. Please
explain the references to the potential purchase of public warrants in this section or
remove.
Directors' Fiduciary Duties and Conflicts of Interest, page 118
5.Please expand your disclosure in this section to highlight the financial conflicts of interest
of your sponsor, officers, directors, advisors and/or your or their affiliates, as the case may
be. For example, highlight, to the extent applicable, conflicts arising from ownership of
the founder shares and private placement shares, including that:
•because of the low price they paid for the founder shares, your sponsor and
your officers and directors may make a substantial profit even if the company selects
an acquisition target that subsequently declines in value and is unprofitable for public
investors;
•if you do not consummate a business combination within the time required, the
founder shares, private placement units, and their underlying securities will expire
FirstName LastNameBihua Chen
Comapany NameHelix Acquisition Corp. II
January 10, 2024 Page 3
FirstName LastName
Bihua Chen
Helix Acquisition Corp. II
January 10, 2024
Page 3
worthless; and
•highlight whether employment or consulting agreements negotiated with a target
business in connection with a business combination, or other agreements providing
for compensation following an initial business combination, may cause your officers
and directors to have a conflict of interest.
Principal Shareholders, page 123
6.Please revise to include Bihua Chen in the beneficial ownership table and include the
shares owned through Helix Holdings II LLC, your sponsor, as reflected in footnote three
to the table. Please also revise the amount held by officers and directors as a group.
Signatures, page II-4
7.Please include the signatures of the majority of the board of directors. See Instruction 1 to
Signatures to Form S-1.
Please contact Paul Cline at 202-551-3851 or Isaac Esquivel at 202-551-3395 if you have
questions regarding the financial statements and related matters. Please contact Ronald (Ron) E.
Alper at 202-551-3329 or Pam Howell at 202-551-3357 with any other questions.
Sincerely,
Division of Corporation Finance
Office of Real Estate & Construction
cc: Joel Rubinstein